Retatrutide Clinical Trial Results: What the TRIUMPH Data Shows
In the Phase 2 NEJM trial, people taking the highest dose of retatrutide lost an average of 24.2% of their body weight in 48 weeks — and every single person on the 8mg or 12mg dose lost at least 5% of their body weight. Every single one.
That number matters because semaglutide (Wegovy) peaks around 15%. Tirzepatide (Zepbound) gets to about 22%. Retatrutide is doing something neither of those drugs could.
Key Takeaways
- Retatrutide is a triple agonist — it activates GLP-1, GIP, and glucagon receptors simultaneously, which is why it outperforms single and dual agonists
- The Phase 2 trial published in the NEJM (2023) showed dose-dependent weight loss from -8.7% to -24.2% across dose groups
- The TRIUMPH Phase 3 program consists of 8 trials covering obesity, type 2 diabetes, sleep apnea, osteoarthritis, cardiovascular disease, and more
- In December 2025, Phase 3 TRIUMPH-4 results reported 28.7% average weight loss at 68 weeks — a new record
- In March 2026, TRANSCEND-T2D-1 results showed significant A1C and weight reductions in type 2 diabetes patients
- Retatrutide is still investigational — FDA approval is expected no earlier than 2026–2027
These numbers are real, and they're extraordinary. But there's still meaningful uncertainty. Phase 3 trials are ongoing, long-term safety data is still accumulating, and "average" doesn't mean "you." Here's what the actual data says, trial by trial.
What Is Retatrutide? A Quick Primer
Retatrutide (LY3437943) is an injectable drug developed by Eli Lilly. You take it once a week — same delivery format as Ozempic or Zepbound. What makes it different is that it hits three metabolic pathways instead of one or two.
Most GLP-1 drugs work by slowing gastric emptying and telling your brain you're full. Tirzepatide added GIP, which amplifies the insulin response and may affect fat cells directly. Retatrutide adds glucagon activation on top of that, which increases energy expenditure and pushes your body to mobilize stored fat more aggressively.
The triple mechanism is why the weight loss numbers are higher. It's not just eating less — it's eating less and burning more efficiently at the same time.
If you want a deeper breakdown of how this drug works at the receptor level, see our guide: What Is Retatrutide?
The Phase 2 NEJM Trial: Where It All Started
The pivotal Phase 2 trial was published in the New England Journal of Medicine in June 2023. It's the foundational dataset. 338 adults with obesity (BMI ≥30, or ≥27 with a comorbidity) and no type 2 diabetes were randomized to receive retatrutide at four dose levels — 1mg, 4mg, 8mg, 12mg — or placebo. The trial ran 48 weeks.
This was a double-blind, placebo-controlled study. The gold standard design. And the results were not subtle.
TRIUMPH Phase 2: Weight Loss Results by Dose (48 Weeks)
| Dose | Mean Weight Loss | ≥5% Weight Loss | ≥10% Weight Loss | ≥15% Weight Loss |
|---|---|---|---|---|
| Placebo | −2.1% | 27% | 9% | 2% |
| 1mg | −8.7% | 73% | 36% | 13% |
| 4mg | −17.1% | 95% | 77% | 53% |
| 8mg | −22.8% | 100% | 91% | 75% |
| 12mg | −24.2% | 100% | 93% | 83% |
Source: NEJM 2023, NCT04881760
A few things stand out. At 12mg, 83% of participants lost at least 15% of their body weight. That 15% threshold is clinically significant — it's the point at which type 2 diabetes remission becomes more likely, cardiovascular risk drops meaningfully, and joint stress starts to ease. Getting 83% of patients there is unheard of.
Beyond weight, cardiometabolic markers improved too: blood pressure dropped, fasting glucose fell, lipid profiles got better. The drug wasn't just moving the scale — it was improving the underlying metabolic picture.
How Phase 2 Numbers Compare to Approved Drugs
Honestly, comparing these drugs can feel like reading stats for athletes in different eras. The trials aren't perfectly matched — different populations, different durations, different designs. But the broad comparison is still useful context for understanding what retatrutide might offer relative to what's already out there.
| Drug | Mechanism | Peak Clinical Trial Weight Loss |
|---|---|---|
| Semaglutide (Wegovy) | GLP-1 only | ~15% (STEP-1, 68 weeks) |
| Tirzepatide (Zepbound) | GLP-1 + GIP | ~22% (SURMOUNT-1, 72 weeks) |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24.2% Phase 2 / 28.7% Phase 3 |
Each step up in mechanism complexity has added roughly 5–7 percentage points of weight loss. Adding glucagon activation seems to be doing the same thing — but the Phase 3 numbers suggest the gap might be even wider at full dosing and longer duration.
The TRIUMPH Phase 3 Program: Overview
Eli Lilly didn't just run one or two Phase 3 trials. They built an entire program called TRIUMPH — Trials of Investigational Medicines for People with obesity and associated comorbidities. Eight trials. Over 5,800 participants globally. Multiple indications being evaluated simultaneously using a novel "basket trial" design.
TRIUMPH Phase 3 Program Overview
| Trial | Population | Duration | Primary Endpoint | Status |
|---|---|---|---|---|
| TRIUMPH-1 | Obesity, no T2D | 80 weeks | % weight change | Ongoing, readout 2026 |
| TRIUMPH-2 | Obesity, no T2D (replication) | 80 weeks | % weight change | Ongoing, readout 2026 |
| TRIUMPH-3 | Obesity + established CVD | Ongoing | CV safety + weight | Ongoing |
| TRIUMPH-4 | Obesity, no T2D (pivotal) | 68 weeks | % weight change | Results: 28.7% loss |
| TRIUMPH-OSA | Obesity + sleep apnea | 52 weeks | AHI reduction | Ongoing |
| TRIUMPH-OA | Obesity + knee OA | 68 weeks | WOMAC score | Ongoing |
| TRANSCEND-T2D-1 | Type 2 diabetes + obesity | ~72 weeks | A1C reduction | Phase 3 results, March 2026 |
| TRIUMPH-NASH | Metabolic liver disease | Ongoing | Liver fat reduction | Ongoing |
This breadth is deliberate. Lilly is positioning retatrutide for multiple indications — not just obesity, but the whole cluster of diseases that obesity drives.
TRIUMPH-4: The 28.7% Result
In December 2025, Eli Lilly released Phase 3 results from TRIUMPH-4. This was the first major Phase 3 efficacy readout, and it exceeded the Phase 2 numbers.
At 68 weeks, participants on the highest dose lost an average of 28.7% of their body weight. That's roughly 58–70 pounds for an average-weight participant in the trial. Not a single competitor drug has posted a number like that in a Phase 3 trial.
A few notes on what this does and doesn't mean for you:
- 28.7% is the mean. Some people lost more. Some lost less.
- The trial had a titration schedule lasting ~16 weeks before hitting maintenance dose. Weight loss was gradual, not a cliff.
- The trial population was adults with obesity — not morbid obesity. Individual results will vary.
- Long-term follow-up data doesn't exist yet. What happens at year 3 or 5 is still unknown.
Still. 28.7% is a big number with a real sample size behind it.
TRANSCEND-T2D-1: March 2026 Phase 3 Results
Fresh data. In March 2026, Lilly announced positive topline Phase 3 results from TRANSCEND-T2D-1 — the first Phase 3 trial specifically in people with type 2 diabetes.
The drug hit both its primary and all key secondary endpoints. Participants saw significant reductions in A1C (blood sugar control) and body weight. Some participants lost up to 16.8% of body weight — exceptional for a diabetes population, where GLP-1 drugs typically underperform compared to their obesity-only trials.
Why does this matter? Because type 2 diabetes and obesity are deeply intertwined. Most people with T2D are also managing their weight. A drug that moves both needles at once — and does it better than current options — would be a meaningful clinical advance. Lilly is likely targeting a dual indication (obesity + T2D) similar to how tirzepatide got both Mounjaro and Zepbound approved.
Beyond Weight: What Else the Trials Are Measuring
This is where retatrutide gets interesting beyond the scale. The Phase 2 data and early Phase 3 signals suggest benefits that go well beyond just losing pounds.
Liver fat: A Nature Medicine study (2024) from a Phase 2 cohort showed retatrutide reduced liver fat by up to 82% in participants with metabolic-associated steatotic liver disease. That's a dramatic number. Non-alcoholic fatty liver disease is one of the most undertreated metabolic conditions, and current options are extremely limited.
Sleep apnea: TRIUMPH-OSA is evaluating whether weight loss with retatrutide reduces the apnea-hypopnea index (AHI) enough to treat obstructive sleep apnea. Semaglutide already got an FDA indication for this — retatrutide may follow.
Cardiovascular outcomes: TRIUMPH-3 is specifically studying people with established cardiovascular disease. The trial is powered to detect whether retatrutide reduces MACE (major adverse cardiovascular events). This is the semaglutide SELECT trial playbook — and if results are positive, it dramatically expands who benefits.
Knee osteoarthritis: TRIUMPH-OA is measuring WOMAC scores (pain and function) in participants with obesity and knee OA. The hypothesis is that weight reduction + potential anti-inflammatory effects could meaningfully reduce joint pain.
The full picture of retatrutide isn't just "better Ozempic." It may end up as a metabolic drug with indications across a dozen different conditions.
What Were the Side Effects in Clinical Trials?
The most common side effects in both Phase 2 and Phase 3 trials were gastrointestinal — nausea, vomiting, diarrhea, and constipation. These are the same side effect profile seen with all incretin-based drugs. They're typically worst early in treatment and improve as your body adjusts.
In the Phase 2 trial, serious adverse events were relatively low and comparable to placebo after the initial titration period. The slow dose escalation schedule — starting at 2mg and increasing over 16 weeks — was specifically designed to minimize GI burden.
A few things worth flagging from the trial data:
- Heart rate increases were observed, similar to other GLP-1 drugs
- Gallbladder-related events (cholelithiasis) appeared in a small percentage of participants
- No unexpected safety signals emerged that weren't already known from the drug class
For a full breakdown of what the side effect data actually shows, see: Retatrutide Side Effects: What the Data Shows
When Could Retatrutide Be Available?
Honestly, this is the question everyone wants answered. Here's the current timeline picture:
- Phase 3 TRIUMPH-1 and TRIUMPH-2 readouts expected mid-to-late 2026
- FDA submission (NDA) expected late 2026
- FDA review period typically 12 months for standard review, 6 months for priority review
- Earliest possible approval is late 2026 or 2027 if things go optimally
These timelines can slip. They often do. The positive TRANSCEND-T2D-1 result in March 2026 is a good sign, but the pivotal obesity trials (TRIUMPH-1 and TRIUMPH-2) haven't reported yet. Those are the data the FDA needs for the primary obesity indication.
If you want to track real before-and-after experiences from early access contexts, see: Retatrutide Before and After
Retatrutide vs Tirzepatide: What the Trials Suggest
People ask this a lot. Lilly is actually running a direct head-to-head Phase 3 trial (TRIUMPH-vs-tirzepatide) comparing the two drugs in adults with obesity. Results aren't in yet.
What we can say from the existing trial data:
- Retatrutide Phase 2 outperformed tirzepatide's Phase 2 (24.2% vs ~21-22%)
- Retatrutide Phase 3 TRIUMPH-4 (28.7%) far exceeds tirzepatide's Phase 3 best (~22.5%)
- These aren't controlled comparisons — different populations, durations, and protocols
The head-to-head will be the definitive answer. But based on mechanism alone, the addition of glucagon activation provides a plausible biological reason for superior efficacy. Glucagon receptor activation pushes energy expenditure — the combination of eating less AND burning more efficiently may simply be additive in a way dual agonism isn't.
Frequently Asked Questions
What is the TRIUMPH trial for retatrutide?
TRIUMPH is Eli Lilly's Phase 3 clinical development program for retatrutide. It stands for Trials of Investigational Medicines for People with obesity and associated comorbidities. The program includes 8 individual trials studying retatrutide across multiple conditions including obesity, type 2 diabetes, sleep apnea, cardiovascular disease, knee osteoarthritis, and liver disease.
How much weight loss did the retatrutide Phase 2 trial show?
The Phase 2 NEJM trial (2023) showed dose-dependent weight loss from -8.7% at the 1mg dose to -24.2% at the 12mg dose over 48 weeks. At the 12mg dose, 100% of participants lost at least 5% of body weight, and 83% lost at least 15%.
What did the retatrutide Phase 3 results show?
TRIUMPH-4, the first Phase 3 efficacy readout (December 2025), reported 28.7% average weight loss at 68 weeks at the highest dose. TRANSCEND-T2D-1 (March 2026) showed significant A1C reductions and up to 16.8% body weight loss in type 2 diabetes patients. Multiple additional Phase 3 readouts are expected throughout 2026.
What does the retatrutide NEJM study say?
The NEJM June 2023 publication reported Phase 2 results showing that retatrutide produced the highest weight loss ever recorded in a clinical trial at the time (24.2% at 48 weeks). The trial was a randomized, double-blind, placebo-controlled study of 338 adults with obesity.
Is retatrutide better than tirzepatide?
Based on available trial data, retatrutide shows higher average weight loss in clinical trials than tirzepatide — 24.2-28.7% versus ~22%. However, these comparisons are not direct head-to-head studies. Eli Lilly is conducting an actual head-to-head comparison trial, which hasn't reported yet. Mechanism-based reasoning suggests the addition of glucagon activation may produce additive benefits, but the definitive answer awaits the direct comparison data.
What are the side effects of retatrutide in clinical trials?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation. These were similar to other GLP-1/GIP-based drugs and were managed through gradual dose escalation. No unexpected safety signals were identified in Phase 2 or the early Phase 3 data available so far.
When will retatrutide be available?
FDA approval is estimated no earlier than late 2026, with 2027 being more realistic. Pivotal Phase 3 trials (TRIUMPH-1 and TRIUMPH-2) are expected to report mid-to-late 2026, followed by an NDA submission. FDA review typically takes 6–12 months.
Where the Research Stands Right Now
The clinical trial evidence for retatrutide is genuinely impressive — more so than any obesity drug that came before it. The Phase 2 data broke records. The Phase 3 TRIUMPH-4 result went higher. The T2D Phase 3 data just came out positive. The mechanism has a clear biological rationale for why the triple agonism works better.
But let's be real about the uncertainty. Two pivotal trials (TRIUMPH-1 and TRIUMPH-2) haven't reported yet. Long-term data past 68–80 weeks doesn't exist. We don't know what happens when you stop — does the weight come back like with other drugs? The cardiovascular outcomes trial is still running. The liver disease trial is still running.
What we have right now is an extremely promising picture with some critical gaps still being filled in. The data that exists is the best weight loss drug data ever generated in controlled trials. The data that doesn't exist yet matters too.
If you're watching this space for yourself or someone you care about, the most important readout to watch for is TRIUMPH-1 — expected in 2026. That's the pivotal obesity trial that drives the FDA submission.
Ready to explore current peptide options while retatrutide works through its trials?
Explore Ascension Peptides
Disclaimer: This article is for educational and informational purposes only. Retatrutide is an investigational drug that has not received FDA approval. All clinical trial data discussed is from published scientific literature, Eli Lilly press releases, and ClinicalTrials.gov. Nothing in this article constitutes medical advice. Consult a licensed healthcare provider before making any medical decisions.
